MedPath

Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance

Phase 2
Completed
Conditions
Hypertension
Ischemic Stroke
Interventions
Behavioral: Behavioral intensification
Device: Bluetooth-equipped sphygmomanometer
Registration Number
NCT03024476
Lead Sponsor
Seoul National University Bundang Hospital
Brief Summary

BOSS-Trial I is a phase 2 clinical trial with the following objectives;

1. to prove the feasibility of a Bluetooth-equipped sphygmomanometer system in real-world clinical practice and wireless connection to the main server;

2. to prove the feasibility of the BP management strategy, including the pre-specified BP range, BP management algorithm, and behavioral; and

3. to gather information for the phase 3 trial including BP variability indices and their potentials as a treatment guidance.

Detailed Description

* Elevated blood pressure is an established risk factor for recurrent stroke and vascular events in ischemic stroke survivors, but

* Current guideline (JNC VIII) has omitted or only partially covered a number of practical and important issues as follow;

* When and how we measure blood pressure?

* Is it justifiable to apply the same blood pressure threshold for office BP and home BP?

* Should stroke survivors be treated by the same BP goal for non-stroke subjects?

* Is it justifiable to apply the universal BP threshold for different mechanisms of ischemic stroke?

* Is it really about only blood pressure or might it really be "beyond blood pressure?"

* Lifestyle modification should accompany all the pharmacological intervention but is usually in adequate to initiate behavioral changes.

* Frequent BP measurement at home will provide more detailed and reliable information than occasional office BP's.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
67
Inclusion Criteria
  • Ischemic stroke survivors within 7 days after onset
  • ≥19 year-old male or female
  • Medically and neurologically stabilized enough to take BP-lowering medication
  • Mean systolic blood pressure ≥135 mm Hg during two days between at least 24 hours after onset and randomization (whether BP-lowering medication was prescribed or not)
  • Capable of taking oral medication
  • Capable of operating a wireless Bluetooth-equipped sphygmomanometer system and being expected to follow required procedures of the clinical trial
  • Patients who provided written informed consent
Exclusion Criteria
  • Pregnant, puerperium ≤30 days or on breastfeeding
  • enrolled in other interventional clinical trial
  • Being transferred to rehabilitation center or institutionalized
  • Being expected to have cerebral artery interventions within 3 months after randomization
  • Known allergic reactions to olmesartan, amlodipine or hydrochlorothiazide
  • Known severe hepatic disease
  • Advanced kidney dysfunction requiring dialysis
  • Being unlikely, in the opinion of the investigator, to comply with the clinical trial protocol or being unsuitable for any other reason.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intensive management armPharmacological intensification based on olmesartanDescription: * Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups). * Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP. * Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.
Intensive management armBluetooth-equipped sphygmomanometerDescription: * Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups). * Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP. * Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.
Intensive management armBehavioral intensificationDescription: * Interventions in the intensive management arm consist of 1) behavioral intensification and 2) pharmacological intensification based on olmesartan * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups). * Regarding behavioral intensification, an automated texting and call for breakthrough visit will be sent from the main server to encourage regular measurements of BP and maintain a desirable goad of BP. * Regarding pharmacological intensification, a specific algorithm for BP-lowering medication prescription will be provided to the responsible physicians by the steering committee.
Control armBluetooth-equipped sphygmomanometerDescription: * Other than a bluetooth-equipped sphygmomanometer, standard managements abiding by the most current guideline will be provided from the responsible physicians. * Participants will be given a Bluetooth-equipped sphygmomanometer, which is connected to the main server through the participants' own smartphone. Every blood pressure and heart rate measured will be encrypted and stored in the main server (Identical for both intervention and control groups).
Primary Outcome Measures
NameTimeMethod
Rate of patients who responded to the calls for breakthrough visitAt 3 months after randomization

ratio of subjects response over the breakthrough visit calls

Retention of included participantsAt 3 months after randomization

Ratio of completed subject over randomized subjects in each group

Control of blood pressureAt 3 months after randomization

ratio of subjects with well-controlled BP in each group

Recruitment time to prespecified number of subjectsAt 3 months after randomization

Difference in days between recruitment of the first subject and last subject

Frequencies of calls for breakthrough visitAt 3 months after randomization

Mean and standard deviation of breakthrough visits per each patient in the intensive management group

Secondary Outcome Measures
NameTimeMethod
Weighted hit score of BPAt 3 months after randomization

When two consecutive hits crossed over or below the margin of desirable BP, give 2x weight. Final score will be generated by dividing by total number of measurements

Hypotensive eventsUntil 3 months after randomization

Complaint of dizzy spells, falls or low-BP related events by patients

Vascular eventsAt 3 months after randomization

Recurrent vascular events including recurrent stroke, myocardial infarction or vascular death

Frequency of out-of-range measurementAt 3 months after randomization

Frequency of BP measurements out of the desirable BP range in a week

Trial Locations

Locations (3)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Gyeonggi, Korea, Republic of

Nowon Eulji Medical Center, Eulji University

🇰🇷

Seoul, Korea, Republic of

Seoul Medical Center

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath